Skip to main content
Top
Published in: BMC Cardiovascular Disorders 1/2016

Open Access 01-12-2016 | Research article

Can BNP-guided therapy improve health-related quality of life, and do responders to BNP-guided heart failure treatment have improved health-related quality of life? Results from the UPSTEP study

Authors: Patric Karlström, Peter Johansson, Ulf Dahlström, Kurt Boman, Urban Alehagen

Published in: BMC Cardiovascular Disorders | Issue 1/2016

Login to get access

Abstract

Background

To investigate whether B-type natriuretic peptide (NP)-guided treatment of heart failure (HF) patients improved their health related quality of life (Hr-QoL) compared to routine HF treatment, and whether changes in Hr-QoL differed depending on whether the patient was a responder to NP-guided therapy or not.

Methods

A secondary analysis of the UPSTEP-study, a Scandinavian multicentre study using a prospective, randomized, open, blinded evaluation design on patients with HF with New York Heart Association (NYHA) class II-IV. NP-guiding was aimed to reduce BNP <150 ng/L if < 75 years or BNP < 300 ng/L if > 75 years. A responder was defined as a patient with a BNP < 300 ng/L and/or a decrease in BNP of at least 40 % in week 16 compared to study start. Short form-36 (SF-36) was used to measure Hr-QoL. At the study start, 258 patients presented evaluable SF-36 questionnaires, 131 in the BNP group and 127 in the control group. At the study end 100 patients in the NP-guided group and 98 in the control group, presenting data from both the study start and the study end.

Results

There were no significant differences in Hr-QoL between NP-guided HF treatment and control group; however significant improvements could be seen in four of the eight domains in the NP-guided group, whereas in the control group improvements could be seen in six of the domains.
Among the responders improvements could be noted in four domains whereas in the non-responders improvements could be seen in only one domain evaluating within group changes.

Conclusions

Improved Hr-QoL could be demonstrated in several of the domains in both the NP-guided and the control group. In the responder group within group analyses showed more increased Hr-QoL compared to the non-responder group. However, all groups demonstrated increase in Hr-QoL.
Appendix
Available only for authorised users
Literature
2.
go back to reference Paren P et al. Trends in prevalence from 1990 to 2007 of patients hospitalized with heart failure in Sweden. Eur J Heart Fail. 2014;16(7):737–42.CrossRefPubMed Paren P et al. Trends in prevalence from 1990 to 2007 of patients hospitalized with heart failure in Sweden. Eur J Heart Fail. 2014;16(7):737–42.CrossRefPubMed
3.
go back to reference Shafazand M et al. Decreasing trends in the incidence of heart failure after acute myocardial infarction from 1993-2004: a study of 175,216 patients with a first acute myocardial infarction in Sweden. Eur J Heart Fail. 2011;13(2):135–41.CrossRefPubMed Shafazand M et al. Decreasing trends in the incidence of heart failure after acute myocardial infarction from 1993-2004: a study of 175,216 patients with a first acute myocardial infarction in Sweden. Eur J Heart Fail. 2011;13(2):135–41.CrossRefPubMed
4.
go back to reference Levy D et al. Long-term trends in the incidence of and survival with heart failure. N Engl J Med. 2002;347(18):1397–402.CrossRefPubMed Levy D et al. Long-term trends in the incidence of and survival with heart failure. N Engl J Med. 2002;347(18):1397–402.CrossRefPubMed
5.
go back to reference Hobbs FD et al. Impact of heart failure and left ventricular systolic dysfunction on quality of life: a cross-sectional study comparing common chronic cardiac and medical disorders and a representative adult population. Eur Heart J. 2002;23(23):1867–76.CrossRefPubMed Hobbs FD et al. Impact of heart failure and left ventricular systolic dysfunction on quality of life: a cross-sectional study comparing common chronic cardiac and medical disorders and a representative adult population. Eur Heart J. 2002;23(23):1867–76.CrossRefPubMed
6.
go back to reference Troughton RW et al. Effect of B-type natriuretic peptide-guided treatment of chronic heart failure on total mortality and hospitalization: an individual patient meta-analysis. Eur Heart J. 2014;35(23):1559–67.PubMedCentralCrossRefPubMed Troughton RW et al. Effect of B-type natriuretic peptide-guided treatment of chronic heart failure on total mortality and hospitalization: an individual patient meta-analysis. Eur Heart J. 2014;35(23):1559–67.PubMedCentralCrossRefPubMed
7.
go back to reference Anker SD et al. The importance of patient-reported outcomes: a call for their comprehensive integration in cardiovascular clinical trials. Eur Heart J. 2014;35(30):2001–9.CrossRefPubMed Anker SD et al. The importance of patient-reported outcomes: a call for their comprehensive integration in cardiovascular clinical trials. Eur Heart J. 2014;35(30):2001–9.CrossRefPubMed
8.
go back to reference Troughton RW et al. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet. 2000;355(9210):1126–30.CrossRefPubMed Troughton RW et al. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet. 2000;355(9210):1126–30.CrossRefPubMed
9.
go back to reference Pfisterer M et al. BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial. JAMA. 2009;301(4):383–92.CrossRefPubMed Pfisterer M et al. BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial. JAMA. 2009;301(4):383–92.CrossRefPubMed
10.
go back to reference Eurlings LW et al. Management of chronic heart failure guided by individual N-terminal pro-B-type natriuretic peptide targets: results of the PRIMA (Can PRo-brain-natriuretic peptide guided therapy of chronic heart failure IMprove heart fAilure morbidity and mortality?) study. J Am Coll Cardiol. 2010;56(25):2090–100.CrossRefPubMed Eurlings LW et al. Management of chronic heart failure guided by individual N-terminal pro-B-type natriuretic peptide targets: results of the PRIMA (Can PRo-brain-natriuretic peptide guided therapy of chronic heart failure IMprove heart fAilure morbidity and mortality?) study. J Am Coll Cardiol. 2010;56(25):2090–100.CrossRefPubMed
11.
go back to reference Bhardwaj A et al. Quality of life and chronic heart failure therapy guided by natriuretic peptides: results from the ProBNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) study. Am Heart J. 2012;164(5):793–9. e1.CrossRefPubMed Bhardwaj A et al. Quality of life and chronic heart failure therapy guided by natriuretic peptides: results from the ProBNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) study. Am Heart J. 2012;164(5):793–9. e1.CrossRefPubMed
12.
go back to reference Persson H et al. Improved pharmacological therapy of chronic heart failure in primary care: a randomized Study of NT-proBNP Guided Management of Heart Failure--SIGNAL-HF (Swedish Intervention study--Guidelines and NT-proBNP AnaLysis in Heart Failure). Eur J Heart Fail. 2010;12(12):1300–8.CrossRefPubMed Persson H et al. Improved pharmacological therapy of chronic heart failure in primary care: a randomized Study of NT-proBNP Guided Management of Heart Failure--SIGNAL-HF (Swedish Intervention study--Guidelines and NT-proBNP AnaLysis in Heart Failure). Eur J Heart Fail. 2010;12(12):1300–8.CrossRefPubMed
13.
go back to reference Lainchbury JG et al. N-terminal pro-B-type natriuretic peptide-guided treatment for chronic heart failure: results from the BATTLESCARRED (NT-proBNP-Assisted Treatment To Lessen Serial Cardiac Readmissions and Death) trial. J Am Coll Cardiol. 2009;55(1):53–60.CrossRefPubMed Lainchbury JG et al. N-terminal pro-B-type natriuretic peptide-guided treatment for chronic heart failure: results from the BATTLESCARRED (NT-proBNP-Assisted Treatment To Lessen Serial Cardiac Readmissions and Death) trial. J Am Coll Cardiol. 2009;55(1):53–60.CrossRefPubMed
14.
go back to reference Gaggin HK et al. Characterization and prediction of natriuretic peptide “nonresponse” during heart failure management: results from the ProBNP Outpatient Tailored Chronic Heart Failure (PROTECT) and the NT-proBNP-Assisted Treatment to Lessen Serial Cardiac Readmissions and Death (BATTLESCARRED) study. Congest Heart Fail. 2013;19(3):135–42.CrossRefPubMed Gaggin HK et al. Characterization and prediction of natriuretic peptide “nonresponse” during heart failure management: results from the ProBNP Outpatient Tailored Chronic Heart Failure (PROTECT) and the NT-proBNP-Assisted Treatment to Lessen Serial Cardiac Readmissions and Death (BATTLESCARRED) study. Congest Heart Fail. 2013;19(3):135–42.CrossRefPubMed
15.
go back to reference Karlstrom P et al. Brain natriuretic peptide-guided treatment does not improve morbidity and mortality in extensively treated patients with chronic heart failure: responders to treatment have a significantly better outcome. Eur J Heart Fail. 2011;13(10):1096–103.CrossRefPubMed Karlstrom P et al. Brain natriuretic peptide-guided treatment does not improve morbidity and mortality in extensively treated patients with chronic heart failure: responders to treatment have a significantly better outcome. Eur J Heart Fail. 2011;13(10):1096–103.CrossRefPubMed
16.
go back to reference Karlstrom P, et al. Responder to BNP-guided treatment in heart failure. The process of defining a responder. Scand Cardiovasc J. 2015;49:316–324. Karlstrom P, et al. Responder to BNP-guided treatment in heart failure. The process of defining a responder. Scand Cardiovasc J. 2015;49:316–324.
17.
go back to reference Sullivan M, Karlsson J, Ware Jr JE. The Swedish SF-36 Health Survey--I. Evaluation of data quality, scaling assumptions, reliability and construct validity across general populations in Sweden. Soc Sci Med. 1995;41(10):1349–58.CrossRefPubMed Sullivan M, Karlsson J, Ware Jr JE. The Swedish SF-36 Health Survey--I. Evaluation of data quality, scaling assumptions, reliability and construct validity across general populations in Sweden. Soc Sci Med. 1995;41(10):1349–58.CrossRefPubMed
18.
go back to reference Loge JH, Kaasa S. Short form 36 (SF-36) health survey: normative data from the general Norwegian population. Scand J Soc Med. 1998;26(4):250–8.PubMed Loge JH, Kaasa S. Short form 36 (SF-36) health survey: normative data from the general Norwegian population. Scand J Soc Med. 1998;26(4):250–8.PubMed
19.
go back to reference Johansson P et al. Measurement of health-related quality of life in chronic heart failure, from a nursing perspective-a review of the literature. Eur J Cardiovasc Nurs. 2004;3(1):7–20.CrossRefPubMed Johansson P et al. Measurement of health-related quality of life in chronic heart failure, from a nursing perspective-a review of the literature. Eur J Cardiovasc Nurs. 2004;3(1):7–20.CrossRefPubMed
20.
go back to reference Ware Jr JE. SF-36 health survey update. Spine (Phila Pa 1976). 2000;25(24):3130–9.CrossRef Ware Jr JE. SF-36 health survey update. Spine (Phila Pa 1976). 2000;25(24):3130–9.CrossRef
21.
go back to reference Ware Jr JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30(6):473–83.CrossRefPubMed Ware Jr JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30(6):473–83.CrossRefPubMed
22.
go back to reference Sullivan M, Karlsson J. The Swedish SF-36 Health Survey III. Evaluation of criterion-based validity: results from normative population. J Clin Epidemiol. 1998;51(11):1105–13.CrossRefPubMed Sullivan M, Karlsson J. The Swedish SF-36 Health Survey III. Evaluation of criterion-based validity: results from normative population. J Clin Epidemiol. 1998;51(11):1105–13.CrossRefPubMed
23.
go back to reference Sneed NV et al. Evaluation of 3 quality of life measurement tools in patients with chronic heart failure. Heart Lung. 2001;30(5):332–40.CrossRefPubMed Sneed NV et al. Evaluation of 3 quality of life measurement tools in patients with chronic heart failure. Heart Lung. 2001;30(5):332–40.CrossRefPubMed
24.
go back to reference McMurray JJ et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993–1004.CrossRefPubMed McMurray JJ et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993–1004.CrossRefPubMed
25.
go back to reference Wyrwich KW et al. Clinically important differences in health status for patients with heart disease: an expert consensus panel report. Am Heart J. 2004;147(4):615–22.CrossRefPubMed Wyrwich KW et al. Clinically important differences in health status for patients with heart disease: an expert consensus panel report. Am Heart J. 2004;147(4):615–22.CrossRefPubMed
26.
go back to reference Grady KL et al. Predictors of quality of life in patients with advanced heart failure awaiting transplantation. J Heart Lung Transplant. 1995;14(1 Pt 1):2–10.PubMed Grady KL et al. Predictors of quality of life in patients with advanced heart failure awaiting transplantation. J Heart Lung Transplant. 1995;14(1 Pt 1):2–10.PubMed
27.
go back to reference Agvall B, Alehagen U, Dahlstrom U. The benefits of using a heart failure management programme in Swedish primary healthcare. Eur J Heart Fail. 2013;15(2):228–36.CrossRefPubMed Agvall B, Alehagen U, Dahlstrom U. The benefits of using a heart failure management programme in Swedish primary healthcare. Eur J Heart Fail. 2013;15(2):228–36.CrossRefPubMed
28.
Metadata
Title
Can BNP-guided therapy improve health-related quality of life, and do responders to BNP-guided heart failure treatment have improved health-related quality of life? Results from the UPSTEP study
Authors
Patric Karlström
Peter Johansson
Ulf Dahlström
Kurt Boman
Urban Alehagen
Publication date
01-12-2016
Publisher
BioMed Central
Published in
BMC Cardiovascular Disorders / Issue 1/2016
Electronic ISSN: 1471-2261
DOI
https://doi.org/10.1186/s12872-016-0221-7

Other articles of this Issue 1/2016

BMC Cardiovascular Disorders 1/2016 Go to the issue